Bristol Myers Squibb to Acquire Editas Medicine for $1.5 Billion

TL;DR

BMS is buying EDNS for $4/share cash, deal expected H1 2025.

AI Summary

Editas Medicine, Inc. announced on December 11, 2024, that it has entered into a definitive agreement to be acquired by Bristol Myers Squibb Company for $4.00 per share in cash, representing a total equity value of approximately $1.5 billion. This transaction is expected to close in the first half of 2025, subject to customary closing conditions.

Why It Matters

This acquisition by a major pharmaceutical company could significantly impact the development and accessibility of gene editing therapies pioneered by Editas Medicine.

Risk Assessment

Risk Level: medium — The acquisition is subject to customary closing conditions, including regulatory approvals, which could delay or prevent its completion.

Key Numbers

• $4.00 — Acquisition Price Per Share (Cash amount Bristol Myers Squibb will pay per share of Editas Medicine.)
• $1.5 billion — Total Equity Value (The total cash value of the acquisition for Editas Medicine.)
• H1 2025 — Expected Closing (The anticipated timeframe for the completion of the acquisition.)

Key Players & Entities

• Editas Medicine, Inc. (company) — Company filing the 8-K
• Bristol Myers Squibb Company (company) — Acquiring company
• $4.00 (dollar_amount) — Per share acquisition price
• $1.5 billion (dollar_amount) — Total equity value of the acquisition
• December 11, 2024 (date) — Date of the definitive agreement
• first half of 2025 (date) — Expected closing period for the acquisition

FAQ

Key Financial Figures

• $0.0001 — ange on which registered Common Stock, $0.0001 par value per share EDIT The Nasdaq Sto
• $55.0 million — expects to incur costs of approximately $55.0 million to $70.0 million related to the Discont
• $70.0 million — costs of approximately $55.0 million to $70.0 million related to the Discontinuation, as it c
• $14.0 million — expects to incur costs of approximately $14.0 million to $18.0 million related to the Reducti
• $18.0 million — costs of approximately $14.0 million to $18.0 million related to the Reduction, primarily con

Filing Documents

• edit-20241211.htm (8-K) — 36KB
• editasmedicineannouncesstr.htm (EX-99.1) — 28KB
• image_0.jpg (GRAPHIC) — 10KB
• 0001650664-24-000141.txt ( ) — 208KB
• edit-20241211.xsd (EX-101.SCH) — 2KB
• edit-20241211_lab.xml (EX-101.LAB) — 21KB
• edit-20241211_pre.xml (EX-101.PRE) — 12KB
• edit-20241211_htm.xml (XML) — 3KB

05 Costs Associated with Exit or Disposal Activities

Item 2.05 Costs Associated with Exit or Disposal Activities. On December 11, 2024, the board of directors (the "Board") of Editas Medicine, Inc. (the "Company") approved the discontinuation of the clinical development of the Company's ex vivo renizgamglogene autogedtemcel ("reni-cel") program (the "Discontinuation") to treat sickle cell disease and transfusion-dependent beta thalassemia. In connection with the Discontinuation, the Board approved a reduction in the Company's employee workforce by approximately 180 positions, or approximately 65% (the "Reduction"). The Company is undertaking the Discontinuation and related Reduction to extend its cash runway and refocus resources on its in vivo pipeline development. The Company expects to substantially complete the Reduction by the end of June 2025. The cost savings from the Discontinuation of the clinical development of reni-cel, other cost containment measures, and the Reduction, are expected to extend the Company's cash runway into the second quarter of 2027. The Company expects to incur costs of approximately $55.0 million to $70.0 million related to the Discontinuation, as it completes the wind-down of various activities related to clinical development of reni-cel, including contract termination costs, impairment charges and non-cash charges, and may also incur additional costs not currently contemplated due to events that may occur as a result of or that are associated with the Discontinuation. The Company additionally expects to incur costs of approximately $14.0 million to $18.0 million related to the Reduction, primarily consisting of severance payments and employee benefit costs. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the Reduction. The charges related to the Discontinuation and Reduction are expected to be substantially incurred through the end of June 2025, when the Discontinuation and related Reduc

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure On December 12, 2024, the Company issued a press release announcing the strategic transition to being an in vivo gene editing company, a pivot to optimize its cost structure, extend its cash runway into the second quarter of 2027, and position the Company to accelerate its intent to achieve in vivo human proof of concept in approximately two years, a copy of which press release is attached hereto as Exhibit 99.1. The information in this Item 7.01, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01 Other Events

Item 8.01 Other Events. The disclosure in Item 2.05 relating to the discontinuation of the clinical development of reni-cel, the reduction in force and the expected extension of the Company's cash runway is incorporated herein by reference. On December 11, 2024, the Board also determined to end the previously announced process to partner or out-license reni-cel.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by the Company on December 12, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) This Report contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words anticipate,'' believe,'' continue,'' could,'' estimate,'' expect,'' intend,'' may,'' plan,'' potential,'' predict,'' project,'' target,'' should,'' would,'' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this Report include statements regarding the expectations related to the costs, timing, and estimated financial impacts of the reduction in workforce, including the estimated expenditures associated with the reduction in workforce, and the potential impact of the discontinuation of the clinical development of reni-cel and reduction in employee workforce on the Company's cash runway and operations. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: the Company's ability to successfully implement the reduction in workforce; the actual charges in implementing the reduction in workforce; changes to the assumptions on the estimated charges associated with the reduction in workforce; and unintended consequences from the discontinuation of the clinical development of reni-cel and reduction in workforce. These and other risks are described in greater detail under the caption "Risk Factors" included in the Company's most recent Ann

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EDITAS MEDICINE, INC. Date: December 12, 2024 By: /s/ Gilmore O'Neill Gilmore O'Neill President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR